Novartis AG (NVS) stock forecast and price target
Price $160.50 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($160.50)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $9.07 | +1.0% | $57.8B |
| Next fiscal year ends December 31, 2027 | $9.93 | +9.5% | $61.7B |
| Next quarter ends December 31, 2026 | $2.23 | +9.9% | $14.8B |
| Quarter after ends March 31, 2027 | $2.27 | +14.1% | $14.3B |
Consensus of the analysts covering Novartis, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 2.1% downside over 12 months. Our discounted cash flow model with moderate assumptions puts Novartis’s intrinsic value about 9% below today’s market value, and it scores 2.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Novartis stock price target?
The average 12-month target from 10 analysts is $157.10, 2.1% below the current price of $160.50 Targets range from $130.00 to $185.00.
Is Novartis a buy according to analysts?
The consensus rating is “Hold” (3 strong buy, 2 buy, 4 hold, 1 sell, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Novartis expected to earn?
Analysts expect EPS of $9.07 for the fiscal year ending December 31, 2026 and $9.93 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.